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BACKGROUND

DISCUSSION

METHODS

▪ Clinical pharmacists play an important role in the care of patients
in hospice/palliative care, particularly for the treatment of pain

▪ The study was conducted from October-December 2019 in coordination with a locallybased pharmacy services organization which works with hospice/palliative care providers
▪ A selected group of pharmacists at the organization identified new hospice/palliative care
admissions as part of their usual clinical care process
▪ The first phase of data collected included patient demographics, type of pain, medication
history, pain intensity and palliative prognosis score (range: 1-100) at the time of
admission; furthermore, it identified whether a recommendation for methadone was made
by the pharmacist based on individual indications/contraindications.
▪ Patients who had recommendations for methadone rendered were followed up with a
second phase of data collection by a member of the research team
▪ Further data collected included whether the provided recommendation was accepted or
not, as well as additional patient information including allergies, comorbidities,
hepatic/renal function, nutritional status pain medication history, current pain intensity
and palliative prognosis score.

▪ One of the core responsibilities of a clinical pharmacist is
recommending and optimizing individualized medication regimens
▪ Methadone, a long-active opioid, is particularly useful for pain
control in many patients in hospice/palliative care, but may be
underutilized

OBJECTIVES
▪ The objective of the study was to evaluate the prevalence of
pharmacist recommendations and subsequent physician
acceptance for the use of methadone for pain in newly admitted
hospice/palliative care patients

▪ This research is currently a work-in-progress
▪ Data was analyzed for 158/159 patients based on adult hospice patient inclusion criteria of the study
▪ The demographic and clinical characteristics of the patients collected through the tool aided the
pharmacists in making a clinical judgement of providing methadone recommendation or not
▪ The mean sample age of the sample was 79.6 years (SD: 13.8 years) (Table 1)
▪ The mean palliative prognosis score was relatively stable between admission and follow-up (37.2 ±
12.2 vs 37.4 ± 12.1) (Table 1)
▪ Majority type of pain among the patients was nociceptive pain (62; 39.2), missing data on type of
pain can limit the decision of providing methadone recommendation (Table 2)
▪ Higher utilization of home hospice compared to other hospice types (121; 76.6%) aligns with the
published literature of this setting (Table 3)
▪ As per the traditional use, the sample population has higher opioids utilization for pain management
compared to other medication categories (153; 96.8) (Table 4)
▪ Based on the pharmacists’ clinical judgments, 37 (23.4%) methadone recommendations were
provided; out of which 8 (21.6 %) were accepted by the physicians within the follow-up period

RESULTS/TABLES

▪ Out of the 8 accepted recommendation, 3 (37.5%) were implemented by the physicians themselves

Table 1. Demographics

Table 5. Types of methadone recommendations
n

Mean (SD)

Height (m)

126

1.6 (0.1)

Weight (kg)

133

65.7 (15.1)

125

23.8 (5.0)

2

BMI (kg per m )

n (%)

Table 4. Type of pain medication

156

Palliative prognosis score at admission
Palliative prognosis score at follow-up

150
146

37.4 (12.0)

Home
Nursing home

Opioids

153 (96.8)

APAP

55 (34.8)

121 (76.6)
22 (13.9)

135

21.2 (24.4)

Assisted living

10 (6.3)

Other

3 (4.2)

Inpatient

4 (2.5)
Gabapentinoids

Table 2. Type of pain
Missing

19 (12.0)

62 (39.2)

Neuropathic

5 (3.2)

Both

4 (21.5)

Missing

57 (36.0)

▪ The common categories of allergies were antibiotics (46; 23.6%) and opioids (31; 15.6%); opioid
allergic subpopulation was administered with alternative opioids for pain management
▪ Clinical outcomes of methadone recommendation accepted patients cannot be extrapolated due to
missing data in the follow-up period

1 (0.6)
Other

6 (3.7)
Neuropathic pain

23 (14.6)

Severe renal impairment

9 (5.7)

Other

6 (3.8)

High opioid tolerance

2 (1.3)

Morphine allergy

3 (1.9)

Refractory to other opioids

2 (1.2)

16 (10.1)

Conclusion

12 (7.6)

Note: One patient can be included in more than one category

Nociceptive

▪ Majority of the patients were diagnosed with cardiovascular diseases as a comorbidity (116; 73.4%);
it aligns with the data regarding common contraindication of prescribing methadone being QTc
prolongation (38; 24.0%)

n (%)
NSAID

n (%)

7 (4.4)

Table 6. Indications for methadone use
Opioid/APAP

Days from date of admission

Addition as adjunctive/adjuvant

n (%)

79.6 (13.8)
37.2 (12.1)

26 (16.5)

Table 3. Hospice type
n (%)

Age (years)

Switch to maintenance treatment

▪ The most common recommendation was for maintenance treatment (26; 16.5%) (Table 5)

Note: One patient can be included in more than one category

▪ Ongoing analysis will continue to assess the data collected to identify patterns in recommendations
that were provided versus those that were not.
▪ Further analysis will provide an opportunity to explore methadone interactions with comorbidities as
a reason for limited acceptance among physicians

